Suppr超能文献

延释型哌甲酯治疗 24 周可改善成年 ADHD 的情绪症状。

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

机构信息

Neurocentre, University Hospital of the Saarland, Homburg/Saar.

出版信息

World J Biol Psychiatry. 2010 Aug;11(5):709-18. doi: 10.3109/15622971003624197.

Abstract

OBJECTIVES

Treatment investigations with methylphenidate in adults with ADHD focus preferentially on the classical psychopathology: inattention, hyperactivity and impulsivity. ADHD-associated emotional symptoms, which are frequently present at least in ADHD subpopulations, were studied rarely. The vast majority of the placebo-controlled trials had observation periods between 4 and 8 weeks. To assess the medium- to long-term effects of extended release methylphenidate (MPH-ER) on emotional symptoms and other psychopathology frequently seen in ADHD patients, we conducted a large-scale, multicenter treatment study.

METHODS

We performed a randomised, 24-week, double-blind, placebo-controlled study in adults with ADHD. The diagnosis was made on the basis of the DSM-IV criteria, which were confirmed by clinical history and a structured psychopathological interview and the use of rating instruments. 363 patients were randomized to MPH-ER or placebo at a ratio of 2:1. The duration of the titration period was 5 weeks followed by a maintainance phase of 19 weeks. The efficacy measures were the observer rated 10-item Emotional Dysregulation Scale (EDS) derived from the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and a self-report, six-item Emotional Lability Scale (ELS) extracted from the long version of the Conners Adult ADHD Self Report Scale (CAARS:S:L). In addition we used the SCL-90-R for the assessment of ADHD associated and comorbid psychopathology.

RESULTS

MPH-ER was statistically superior to placebo in reducing emotional symptoms as assessed by the EDS and the ELS. Obsessive-compulsive symptoms and those of problems with self-concept declined until the end of the observation period. The decline was more pronounced in MPH-ER treated individuals. The effects remained robust during the entire maintenance period until week 24. Symptoms of anxiety, depression, anger and hostility, phobia, paranoid ideations and psychoticism were not improved.

CONCLUSIONS

MPH-ER appears to be an efficacious treatment for emotional symptoms with ADHD. Also obsessive-compulsive symptoms and problems with self-concept were affected positively.

摘要

目的

在注意力缺陷多动障碍(ADHD)成人患者中,使用哌甲酯治疗的研究主要集中在经典的精神病理学方面:注意力不集中、多动和冲动。然而,ADHD 相关的情绪症状在至少 ADHD 亚群中经常存在,却很少被研究。绝大多数安慰剂对照试验的观察期为 4 至 8 周。为了评估缓释哌甲酯(MPH-ER)对 ADHD 患者中经常出现的情绪症状和其他精神病理学的中至长期影响,我们进行了一项大规模、多中心的治疗研究。

方法

我们对成人 ADHD 患者进行了一项随机、24 周、双盲、安慰剂对照研究。该诊断基于 DSM-IV 标准,通过临床病史和结构化精神病理学访谈以及使用评分工具进行确认。363 名患者按照 2:1 的比例随机分为 MPH-ER 组或安慰剂组。滴定期持续 5 周,随后维持期 19 周。疗效评估指标为观察评分的 10 项情绪失调量表(EDS),该量表源自 Wender-Reimherr 成人注意缺陷障碍量表(WRAADDS);以及自我报告的六项情绪不稳定性量表(ELS),该量表从 Conners 成人 ADHD 自评量表(CAARS:S:L)的长版本中提取。此外,我们还使用 SCL-90-R 评估 ADHD 相关和共病的精神病理学。

结果

MPH-ER 在降低 EDS 和 ELS 评估的情绪症状方面,统计学上优于安慰剂。强迫症症状和自我概念问题的症状在观察期间持续下降。在 MPH-ER 治疗的个体中下降更为明显。这些效果在整个维持期直至第 24 周都保持稳健。焦虑、抑郁、愤怒和敌意、恐惧症、偏执观念和精神病性症状并未改善。

结论

MPH-ER 似乎是治疗 ADHD 情绪症状的有效治疗方法。强迫症症状和自我概念问题也得到了积极的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验